University of Texas Sells Anticancer Drug Platform to the IQ Group Global

University of Texas Sells Anticancer Drug Platform to the IQ Group Global

The University of Texas has sold its TEX-Core anticancer drug platform to an enterprise dedicated to developing early stage bioscience assets known as IQ Group Global.  TEX-Core, an anticancer drug platform, that has the ability to develop a range of well tolerated, MRI-detectable cancer therapeutics that target drug sensitive and drug-resistant tumors.
TrialSite News follows with a breakdown of this deal, the players, and the potential via our question and answer format.
What is TEX-Core?
An anticancer drug platform that possesses the ability for developers to harness a range of well-tolerated, MRI-detectable cancer therapeutics that target drug-sensitive and drug resistant tumors. The CEO of the IQ Group Global called TEX-Core “A landmark development in oncology that will significantly improve the efficacy of platinum-based cancer therapeutics.”
What will be the first cancer therapeutic IQ Group Global will develop?
The first cancer therapeutic to be commercialized from the platform is OxaliTEX, a novel chemical entity (WO 2015/191797) that targets only solid tumor cells, activates within the tumor and overcomes drug-resistance mechanisms within minimal side effects.
How fa...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee